Use of a super active luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia
- 1 September 1984
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 91 (9), 913-916
- https://doi.org/10.1111/j.1471-0528.1984.tb03708.x
Abstract
An LHRH agonist, D-Ser(But)6des Gly10-LHRH ethylamide, was administered intranasally to 4 women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side-effects, although the pattern of loss returned to pretreatment levels within 2 mo. of ceasing therapy.This publication has 9 references indexed in Scilit:
- Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.BMJ, 1983
- FERTILITY AFTER CHILDBIRTH: INFANT FEEDING PATTERNS, BASAL PRL LEVELS AND POST‐PARTUM OVULATIONClinical Endocrinology, 1982
- INTRANASAL LHRH AGONIST TREATMENT FOR INHIBITION OF OVULATION IN WOMEN: CLINICAL ASPECTSClinical Endocrinology, 1982
- Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?Contraception, 1981
- REDUCTION OF MENSTRUAL BLOOD LOSS BY DANAZOL IN UNEXPLAINED MENORRHAGIA: LACK OF EFFECT OF PLACEBOBJOG: An International Journal of Obstetrics and Gynaecology, 1980
- MORTALITY AMONG WOMEN PARTICIPATING IN THE OXFORD/FAMILY PLANNING ASSOCIATION CONTRACEPTIVE STUDYThe Lancet, 1977
- Determination of Menstrual Blood LossScandinavian Journal of Clinical and Laboratory Investigation, 1964